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Low-risk alpha-human papillomaviruses (HPV) have never been to the fore in HPV 2 research, due to their connection with benign neoplasm only. However, interest in these 3 genotypes has increased substantially in recent years, due to the fact that quadrivalent HPV 4 vaccine contains, in addition to a "cervical cancer component" (against HPV16 and HPV18),
5
virus-like particles of the two most important low-risk alpha-HPV genotypes: HPV6 and 6 HPV11. These two closely related HPV genotypes are the etiological agents of at least 90% 7 of genital warts and laryngeal papillomas (1) (2) (3) (4) and at least 12.1% of cervical low-risk 8 squamous intraepithelial lesions (5) . In phase III clinical trials, this quadrivalent prophylactic
9
HPV vaccine was shown to be highly effective against genital warts, e.g., reducing the 
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The Hybrid Capture 2 HPV DNA Test (hc2) originally developed by Digene Corporation
16
(Gaithersburg, MD) and currently marketed by Qiagen (Hilden, Germany), is the most widely 17 used molecular method for the detection of a subset of clinically important HPV genotypes 18 (7) (8) (9) (10) . In this assay, exfoliated cells are first treated with alkali-denaturating reagent, and the cross-reactivity with several untargeted HPV genotypes (9, (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . This phenomenon 7 certainly reduces the analytical specificity of the high-risk cocktail, but cross-reactivity with 8 some HPV genotypes has proven to be clinically beneficial (11, 12) .
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The US version of hc2, containing the high-risk probe cocktail only, is approved by the 10 US Food and Drug Administration (FDA) for triage of equivocal cytology, atypical squamous 11 cells of undetermined significance (ASCUS), to determine which patients should be referred 12 to colposcopy, and as an adjunctive screening test to cytology in women 30 years and older 13 (10) . Although the use of the hc2 low-risk probe cocktail is not recommended in the US due genotypes, the specificity of the hc2 low-risk cocktail has never been studied in detail.
20
According to the data presented in the hc2 package insert, the only recognized cross-21 reactivity of the hc2 low-risk cocktail is with HPV13, a genotype commonly detected in lip 22 lesions of certain ethnic groups, but never in anogenital lesions (24) . In the present study, AJ620205, U31788 and U31791, respectively. As shown in Table 2 , two primers and two 7 hybridization (FRET) probes were selected for each HPV genotype studied. A common 8 probe was designed for HPV44 and HPV55, which has been recently recognized as a 9 subtype of HPV44 and is no longer considered a separate genotype (26) . A BLAST search of 10 the GenBank nr database was performed for each sequence in order to verify HPV genotype 11 specificity. The assays were set up on the LightCycler 2.0 Real-Time System (Roche
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Diagnostics GmbH, Mannheim, Germany) and performed using a QuantiTect Probe PCR kit
13
(Qiagen, Hilden, Germany), according to the manufacturer's instructions.
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As summarized in Table 1 , the presence of at least one targeted HPV genotype was 
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Finally, all remaining HPV negative samples were tested using an in-house GP5+/GP6+
24
PCR targeting a 150-bp fragment of the L1 gene (27) . HPV genotypes were determined by 25 sequencing the GP5+/GP6+ PCR-products. By using three additional genotyping methods, 
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Finally, in 23 (8.0%) of 285 samples recognized as HPV positive using the hc2 low-risk 3 probe cocktail, no HPV DNA was detected using all seven genotyping methods (Table 1) .
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Focusing on five hc2 targeted HPV genotypes, the presence of HPV6 and HPV11 was 5 excluded using four different and very sensitive PCR-based methods and the presence of 
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In conclusion, in the present genotyping study, which was performed on 285 hc2 low-risk
23
HPV positive cervical specimens, we found that the hc2 low-risk probe cocktail, similarly to 24 the hc2 high-risk cocktail, cross-reacts with several untargeted HPV genotypes. The broader
25
HPV genotype detection range of the hc2 low-risk probe cocktail than is assigned, is clinically 
